|
November 13, 2023
|
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
|
|
November 6, 2023
|
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
|
|
October 30, 2023
|
Biora Therapeutics Submits Updated IND Application for BT-600
|
|
October 23, 2023
|
Biora Therapeutics to Submit Updated IND Application for BT-600
|
|
October 5, 2023
|
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
|
|
September 25, 2023
|
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
|
|
September 19, 2023
|
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
|
|
September 11, 2023
|
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
|
|
September 5, 2023
|
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
|
|
August 14, 2023
|
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
|